Cynata Therapeutics Ltd News

Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial

Cynata Therapeutics (ASX:CYP) completed patient enrolment in its Phase 1 clinical trial of its topical wound dressing product candidate, CYP-006TK, in diabetic foot ulcers, according to a Monday filin

MT NewswiresApr 7 20:19 ET

Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial

Cynata Therapeutics (ASX:CYP) has secured regulatory and ethics approval from the European Union for the phase 2 clinical study of CYP-001 in high-risk acute graft versus host disease, according to a

MT NewswiresMar 19 19:34 ET

Cynata Therapeutics' Breakthrough in Regenerative Medicine

Peter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata Therapeutics. Cynata is a clinical stage stem cell and regenerative medicine company. Their ASX code i

sharecafeMar 13 18:30 ET

Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%

Cynata Therapeutics (ASX:CYP) dosed the first patient in its phase two trial investigating the use of the cellular therapy CYP-001 in patients with graft versus host disease. The randomized trial aims

MT NewswiresMar 4 23:22 ET

Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%

Cynata Therapeutics (ASX:CYP) appointed Mathias Kroll as chief business officer, effective mid-April, the clinical-stage biotechnology company said Thursday. Kroll will join Cynata from QIMR Berghofer

MT NewswiresFeb 28 23:09 ET

Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024

Cynata Therapeutics (ASX:CYP) said it's expecting initial results in the Phase 1 clinical trial of its topical wound dressing product candidate CYP-006TK in diabetic foot ulcer in the first quarter of

MT NewswiresDec 27, 2023 22:05 ET

Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial

Cynata Therapeutics (ASX:CYP) completed the recruitment of 321 participants for a phase three trial investigating the use of cell therapy CYP-004 to treat osteoarthritis, the stem cell and regenerativ

MT NewswiresDec 12, 2023 23:10 ET

Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%

Cynata Therapeutics (ASX:CYP) received regulatory and ethics approval to commence its phase II clinical trial of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD) at clinic

MT NewswiresDec 7, 2023 00:17 ET

Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate

Cynata Therapeutics (ASX:CYP) received a AU$2.3 million research and development tax incentive refund for the 2022/2023 fiscal year. The rebate enables further investment toward advancing the company'

MT NewswiresNov 13, 2023 21:23 ET

Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial

Cynata Therapeutics (ASX:CYP) secured clearance from an independent data safety and monitoring board to advance a phase three trial investigating the use of the stem cell therapy CYP-004 in patients w

MT NewswiresNov 6, 2023 05:42 ET

Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial

Cynata Therapeutics (ASX:CYP) opened the enrollment phase for a phase two clinical trial investigating the use of the cell therapy CYP-001 in high-risk acute graft versus host disease patients. The ra

MT NewswiresAug 10, 2023 03:22 ET

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Yahoo FinanceFeb 5, 2023 21:43 ET

Cynata Therapeutics (ASX:CYP) Receives Approval for Acute Graft-versus-host Disease Clinical Trial

The Market HeraldJan 29, 2023 22:51 ET